A Phase 2 interventional study of EDP167 100mg and EDP167 200mg in Mixed Dyslipidemia, sponsored by Eddingpharm (Zhuhai) Co., Ltd.. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Eddingpharm (Zhuhai) Co., Ltd. · Phase 2, Interventional, and Treatment
Among 72 studies in Dyslipidemias with a site in China — 20 open to participants now, 30 under way, 10 of them phase 3. Dyslipidemias · China.
Among the 72 studies in Dyslipidemias with a site in China, this one is the 37th largest by planned enrollment of the 56 interventional ones, is one of 7 that started in 2026, is one of 5 in phase 2, reaches primary completion later than 19 of the 29 other live ones, and was the 70th registered.
1,247 studies on the registry are indexed under Dyslipidemias; 175 are open to participants now.
This study's planned enrollment of 144 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Browse Dyslipidemias studies →20 of the 72 studies in Dyslipidemias with a site in China are open now, in 12 countries. Each count lists the studies.
Of the 111 Dyslipidemias studies recruiting now, 55 (50%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →72 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 7 started in 2026.
Median enrollment 213 across the 56 interventional studies, 1,000 across the 16 observational. Of the 33 that completed or were terminated, 8 (24%) have results posted.
28 of 72 have an industry lead sponsor. The 10 most frequent:
Eddingpharm (Zhuhai) Co., Ltd. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Eddingpharm (Zhuhai) Co., Ltd. has 3 studies filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
7 of the studies in Dyslipidemias with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT05399992Novartis PharmaceuticalsStudy Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD | 2026-11-23 |
| NCT05749874China National Center for Cardiovascular DiseasesEffects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus | 2026-12-31 |
| NCT07350486First Hospital of China Medical UniversityLLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia | 2027-03-31 |
| NCT07235046Novartis PharmaceuticalsA Study of DII235 in Adults With Elevated Lipoprotein(a) | 2027-04-26 |
Among the 72 studies in Dyslipidemias with a site in China, from their registry updates:
EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting angiopoietin-like 3 protein (ANGPTL3), which may bring benefits for patients with dyslipidemia conditions. This Phase 2 clinical study comprises two phases: a randomized, double-blind, placebo parallel-controlled core study and an open-label extension study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: EDP167 100mg
Drug: EDP167 200mg
Drug: EDP167 300mg
EDP167 100 mg or volume-matched placebo sc once every 12 weeks in the core study, and EDP167 100 mg once every 3 months in the extension study.
EDP167 200 mg or volume-matched placebo sc once every 12 weeks in the core study, and EDP167 200 mg once every 3 months in the extension study.
EDP167 300 mg or volume-matched placebo sc once every 12 weeks in the core study, and EDP167 300 mg once every 3 months in the extension study.
Percentage Change from Baseline in Serum Triglycerides (TG) Levels at Week 24
Time frame: From baseline to week 24 of the core study
Percentage and absolute change of TG, LDL-C, non-HDL-C, TC, VLDL-C, HDL-C, ApoB and ANGPTL3 from baseline to Week 24 (excluding the primary endpoint)
Time frame: From baseline to week 24 of the core study
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.
Of 35 industry-sponsored phase 2 interventional studies under Dyslipidemias, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 12 months is close to that.
Counting every sponsor, half of 43 studies reached it within 13 months; a quarter within 7 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: EDP167
Eddingpharm (Zhuhai) Co., Ltd.